Molecular Evolution of Ear ly-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories Graphical
暂无分享,去创建一个
Takafumi N. Yamaguchi | R. Eils | J. Korbel | P. Boutros | C. Plass | R. Bristow | D. Gordenin | M. Schlesner | G. Sauter | M. Yaspo | B. Brors | T. Schlomm | V. Amstislavskiy | Benjamin Raeder | M. Graefen | H. Huland | M. Kluth | C. Hube-Magg | J. Weischenfeldt | C. Lawerenz | D. Strand | H. Warnatz | D. Schilling | P. Lutsik | O. Bogatyrova | C. Kalle | S. Matzk | C. Koop | J. Meiners | Gervaise H. Henry | Alicia Malewska | C. Feuerstein | Eva-Maria Schmitz | E. Reisinger | Douglas W. Strand | T. Yamaguchi | Pavlo Lutsik
[1] S. Fröhling,et al. Analysis of mutational signatures with yet another package for signature analysis , 2020, Genes, chromosomes & cancer.
[2] Natalie S. Fox,et al. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression , 2018, Cell.
[3] J. Weinstein,et al. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. , 2018, Cell.
[4] Christoph Plass,et al. Enrichment analysis with EpiAnnotator , 2018, Bioinform..
[5] Y. Shin,et al. ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells , 2017, Oncogenesis.
[6] C. Boerkoel,et al. FOXP1 haploinsufficiency: Phenotypes beyond behavior and intellectual disability? , 2017, American journal of medical genetics. Part A.
[7] J. Korbel,et al. Genomes of early onset prostate cancer , 2017, Current opinion in urology.
[8] D. Strand,et al. OMIP‐040: Optimized gating of human prostate cellular subpopulations , 2017, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[9] Takafumi N. Yamaguchi,et al. TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer , 2017, Nature Genetics.
[10] Stefan J. Barfeld,et al. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. , 2017, Cell reports.
[11] Michael P. Schroeder,et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations , 2017, Genome Medicine.
[12] K. Cooney,et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. , 2017, European urology.
[13] Min A. Jhun,et al. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort , 2017, Oncotarget.
[14] Stefan J. Barfeld,et al. c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks , 2017, EBioMedicine.
[15] Shijie C. Zheng,et al. Cell-type deconvolution in epigenome-wide association studies: a review and recommendations. , 2017, Epigenomics.
[16] D. Neal,et al. Asporin is a stromally expressed marker associated with prostate cancer progression , 2017, British Journal of Cancer.
[17] Alain Bergeron,et al. Genomic hallmarks of localized, non-indolent prostate cancer , 2017, Nature.
[18] F. Orso,et al. The RNA-binding protein ESRP1 promotes human colorectal cancer progression , 2016, Oncotarget.
[19] Bin Zhu,et al. Edinburgh Research Explorer Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors , 2022 .
[20] Nancy R. Zhang,et al. Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing , 2016, Proceedings of the National Academy of Sciences.
[21] Ahmet Zehir,et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.
[22] Neva C. Durand,et al. Juicer Provides a One-Click System for Analyzing Loop-Resolution Hi-C Experiments. , 2016, Cell systems.
[23] David C. Jones,et al. Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.
[24] Jeffrey M. Bhasin,et al. Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer. , 2015, Cell reports.
[25] A. Butte,et al. Systematic pan-cancer analysis of tumour purity , 2015, Nature Communications.
[26] Kin Chan,et al. Clusters of Multiple Mutations: Incidence and Molecular Mechanisms. , 2015, Annual review of genetics.
[27] M. Stratton,et al. Clock-like mutational processes in human somatic cells , 2015, Nature Genetics.
[28] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[29] Paola Lecca,et al. Defining order and timing of mutations during cancer progression: the TO-DAG probabilistic graphical model , 2015, Front. Genet..
[30] Gad Getz,et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers , 2015, Nature Genetics.
[31] W. Kraus,et al. groHMM: a computational tool for identifying unannotated and cell type-specific transcription units from global run-on sequencing data , 2015, BMC Bioinformatics.
[32] C. Swanton,et al. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. , 2015, Cancer discovery.
[33] Faraz Hach,et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.
[34] Neva C. Durand,et al. A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping , 2014, Cell.
[35] Dmitry A. Gordenin,et al. Hypermutation in human cancer genomes: footprints and mechanisms , 2014, Nature Reviews Cancer.
[36] Thomas Lengauer,et al. Comprehensive Analysis of DNA Methylation Data with RnBeads , 2014, Nature Methods.
[37] K. Miyazawa,et al. Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) Suppress Cancer Cell Motility via Different Mechanisms* , 2014, The Journal of Biological Chemistry.
[38] Giancarlo Mauri,et al. CAPRI: Efficient Inference of Cancer Progression Models from Cross-sectional Data , 2014, bioRxiv.
[39] Amos Tanay,et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. , 2014, Cell reports.
[40] Peter A. Jones,et al. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer , 2014, Genome research.
[41] Zhaohui S. Qin,et al. Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.
[42] R. Young,et al. Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.
[43] Thomas Whitington,et al. Transcription Factor Binding in Human Cells Occurs in Dense Clusters Formed around Cohesin Anchor Sites , 2013, Cell.
[44] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[45] Steven A. Roberts,et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.
[46] J. Korbel,et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.
[47] D. Zheng,et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.
[48] Heng Li. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.
[49] V. Beneš,et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.
[50] Martin J. Aryee,et al. DNA Methylation Alterations Exhibit Intraindividual Stability and Interindividual Heterogeneity in Prostate Cancer Metastases , 2013, Science Translational Medicine.
[51] R. Weksberg,et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray , 2013, Epigenetics.
[52] D. Rowley,et al. The reactive stroma microenvironment and prostate cancer progression. , 2012, Endocrine-related cancer.
[53] M. Rubin,et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. , 2012, Cancer discovery.
[54] V. Beneš,et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..
[55] Steven A. Roberts,et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. , 2012, Molecular cell.
[56] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[57] Devin C. Koestler,et al. DNA methylation arrays as surrogate measures of cell mixture distribution , 2012, BMC Bioinformatics.
[58] Manolis Kellis,et al. ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.
[59] T. H. van der Kwast,et al. NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy , 2011, Clinical Cancer Research.
[60] I. Mills,et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis , 2011, The EMBO journal.
[61] M. Delorenzi,et al. Identification of Prognostic Molecular Features in the Reactive Stroma of Human Breast and Prostate Cancer , 2011, PloS one.
[62] C. Glass,et al. Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA , 2011, Nature.
[63] T. Russo,et al. Direct targets of Klf5 transcription factor contribute to the maintenance of mouse embryonic stem cell undifferentiated state , 2010, BMC Biology.
[64] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[65] Francesca Demichelis,et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.
[66] M. Robinson,et al. A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.
[67] Aaron R. Quinlan,et al. BIOINFORMATICS APPLICATIONS NOTE , 2022 .
[68] B. Williams,et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.
[69] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[70] J. Wang-Rodriguez,et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[71] Ron Shamir,et al. CLICK and EXPANDER: a system for clustering and visualizing gene expression data , 2003, Bioinform..
[72] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[73] Olivier Gascuel,et al. Fast and Accurate Phylogeny Reconstruction Algorithms Based on the Minimum-Evolution Principle , 2002, WABI.
[74] T. Stamey,et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.
[75] D. Chan,et al. Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .
[76] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[77] H. Huland,et al. Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. , 1997, The Journal of urology.